BRAF V600E Mutations In Papillary Thyroid Carcinoma
Recruitment status was Recruiting
The purpose of this study is to determine whether BRAF V600E mutation in our patients with papillary thyroid cancer has an association with poor prognosis.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Association Of Prognosis And BRAF V600E Mutations In Papillary Thyroid Carcinoma|
- BRAF V600E MUTATION [ Time Frame: 2 years ] [ Designated as safety issue: No ]
|Study Start Date:||July 2011|
|Estimated Study Completion Date:||July 2012|
|Estimated Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
Experimental: BRAF V600E POSITIVITY
This mutation will be analysed using the tumor tissues of the patients operated for thyroid diseases and diagnosed with papillary thyroid carcinoma. And mutation positive patients will be investigated for the aggressive characteristics of the tumor.
Genetic: BRAF V600E POSITIVITY
BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.
Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and BRAF V600E mutation is the most common genetic alteration identified in PTC, ranging from 25 to 80%, with the average rate about 45%. Various studies demonstrated a relationship between BRAF V600E mutation and aggressive characteristics of the cancer, including the worse patient prognosis. But,there are no studies from Turkey regarding this topic. So the investigators will examine BRAF V600E mutation in our patients with PTC and try to assess the role of this mutation in prognosis and further management of the patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01417442
|Yeliz Emine Ersoy||Recruiting|
|Istanbul, Turkey, 34308|
|Contact: Yeliz E Ersoy, DR +905326102713 firstname.lastname@example.org|
|Principal Investigator: Yeliz E Ersoy, M.D.|